WuXi AppTec lifts 2026 revenue outlook after nine-month sales rise 39%
WuXi AppTec's nine-month revenue rose 39% and the company raised its 2026 revenue and free cash flow guidance.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Reuters, China-based drug development services firm WuXi AppTec reported nine-month revenue up 39% year over year. Adjusted net profit attributable to owners also increased sharply over the same period.
The company raised its 2026 total revenue guidance to 61.0-61.9 billion yuan from 58.5-60.5 billion. Its adjusted free cash flow forecast moved up to 14.5-15.5 billion yuan. Management credited the chemistry segment, where late-stage pipeline progress and new capacity drove growth.
why it matters
For investors, the update signals continued demand for contract drug development services, particularly in tides modalities. Analysts, per LSEG data, rate the shares as a average buy, with a median 12-month target about 26.9% above the October 26 close. The news concerns one company and says little about the broader market.
market impact
WuXi AppTec shares and China's biotech sector: higher revenue guidance supports interest in the stock.
tags
instruments
sources
- China's WuXi AppTec nine-month revenue rises on chemistry segment growth; lifts 2026 outlook — Reuters, 26 October 2026 at 09:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗